Discussion
How can the adaptive immune system be targeted as a therapeutic approach for PD?
Neuroinflammation is proposed to be a major factor in creating a toxic environment in the PD brain. However, what is the contribution of the adaptive immune system (ie. T cell function) to PD pathogenesis, and how can we target this system for future therapeutic approaches?
Responses:
Microglia and alpha-synuclein
Reference:
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE. 2010;5(1):e8784.
Immunotherapy for ...
Comment on Reynolds et al 2010
Reference:
Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley LR, Gendelman HE. Regulatory T cells attenuate th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol. 2010;184(5):2261-71.
Microglia modulation of ...
Reference:
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE. 2010;5(1):e8784.
